Hexa Reports Industry Pneumonia Therapeutics Market | Page 2

In the present scenario, there are 12 drugs under investigation in phase III trials, 4 drugs under phase II, and 3 drugs under phase I trial. The aforementioned factors exemplify the consistent efforts being made by the market players. For instance, Omadacycline, a tetracycline under phase III clinical trial, developed by Paratek Pharmaceuticals is being investigated for use in the treatment of ventilator-associated and community- acquired bacterial pneumonia. Further key findings from the report suggest:  Vaccines accounted for the largest share in the product segment in 2016. This can be attributed to their high efficacy and growing inclination of patients toward preventive measures  They are also expected to grow at a lucrative rate owing to the recommendation by WHO for their inclusion in national immunization programs  Drugs are expected to witness moderate growth rate throughout the forecast period. This is believed to be a result of the infiltration of generic drugs that are more cost-efficient.  North America accounted fora substantial share in the market owing toincreasing number of supportive government initiatives and high awareness levels amongst the end-users  Asia Pacific is expected to witness exponential CAGR during the forecast period owing to its high disease burden and continual infrastructural upgradation of research & manufacturing facilities in the region  High competition has been observed in the market, where major players adopt strategies such as new product development, collaborations,and strategic agreements to gain market share Request A Sample copy of This Report @ https://www.hexareports.com/report/pneumonia-therapeutics-market/request-sample Table Of Content Chapter 1 Research Methodology & Scope 1.1 Region-wise Market Calculation 1.2 Region-based Segment Share Calculation 1.3 List of Secondary Sources Chapter 2 Executive Summary 2.1 Region Wise Market Calculation Chapter 3 Pneumonia Therapeutics Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.2 Market Driver Analysis Follow Us: